| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.8 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.009 | 0.8 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.0073 | 0.8 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.0096 | 0.8 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.9 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.9 |